Comparative evaluation of some pharmacological properties and side effects of D-glucitol hexanicotinate (sorbinicate) and nicotinic acid correlated with the plasma concentration of nicotinic acid.
In rabbits kept on a diet containing 1 g/day cholesterol for 12 weeks, the nicotinic acid derivative sorbinicate displayed greater hypolipemic and antiatherogenic activity than an equidose of plain nicotinic acid at much lower and more constant plasma nicotinic acid levels. In normocholesterolemic rats, nicotinic acid given at a level of 300 mg/kg per dose for 3 weeks induced plasma FFA and triglyceride rebound and triglyceride accumulation in the liver and possibly in the heart (all parameters determined 24 h after the last dosing), whereas an equidose of sorbinicate was free from these effects, potentially the two most dangerous side effects of nicotinic acid. By modulating the bioavailability of nicotinic acid, sorbinicate maintains and in some cases enhances the pharmacological activity of the acid, avoiding at least some of its major side effects.
D000818:Animals; D001011:Aorta / Q000032:analysis; D001161:Arteriosclerosis / Q000188:drug therapy; D002784:Cholesterol; D007700:Kinetics; D008055:Lipids / Q000097:blood; D008099:Liver / Q000032:analysis; D008297:Male; D009539:Nicotinic Acids / Q000009:adverse effects / Q000097:blood / Q000494:pharmacology*; D011817:Rabbits; D051381:Rats; D013012:Sorbitol / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000494:pharmacology
D008055:Lipids; D009539:Nicotinic Acids; C015238:glucitol hexanicotinate; D013012:Sorbitol; D002784:Cholesterol